TY - JOUR T1 - Additional response to the correspondence: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Cantini and Bennuci JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2018-213342 SP - annrheumdis-2018-213342 AU - Marc Scherlinger AU - Thierry Schaeverbeke Y1 - 2018/03/13 UR - http://ard.bmj.com/content/early/2018/03/13/annrheumdis-2018-213342.abstract N2 - We read with great interest Cantini and Benucci’s response to our letter.1 However, we would like to add some points to the debate.To date and to our knowledge, every single clinical trial investigating efficacy and safety of biosimilars in rheumatology using a double-blinded design has failed to report any clinical difference with the original biologic. The double-blinded controlled trial NOR-SWITCH as well as open-label extension studies such as PLANETRA investigating efficacy and safety of the switch from original to biosimilar infliximab also failed to report any difference.2 3 These studies unequivocally condone the grade 1b recommendation 6 regarding the efficacy and safety of the switch published … ER -